Table 7.
Proportion (%) of bacterial isolates susceptible in vitro to commonly available antimicrobials
| Penicillin/amoxicillin | Chloramphenicol | Co-trimoxazole | Gentamicin | |
|---|---|---|---|---|
| Non-typhi Salmonella* | 49/148 (33) | 53/153 (35) | 49/145 (34) | 147/152 (97)† |
| Strep pneumoniae | 51/51 (100) | 41/48 (85) | 22/45 (49) | – |
| Haemophilus influenzae | 12/38 (32) | 16/38 (42) | 2/28 (7) | 22/23 (96) |
| E coli | 2/21 (10) | 5/18 (28) | 1/20 (5) | 9/20 (45) |
| Staph aureus | 1/15 (7) | 11/13 (85) | 10/14 (71) | 13/16 (81) |
Susceptibility includes “full” or “intermediate” susceptibility and follows Clinical Laboratory Standards Institute (CLSI) guidelines with exception of susceptibility of Salmonella isolates (noted below).20
*Salmonella isolates were multi-resistant (resistant to amoxicillin, chloramphenicol, and co-trimoxazole) in 85/141 (60.3%) cases.
†Salmonella susceptibilities to gentamicin are shown as actual in vitro results, although CLSI guidelines recommend that for clinical practice all Salmonella should be reported as “not susceptible” owing to poor intracellular penetration of gentamicin.